Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report-Reference-Cited by-同舟云学术

Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report

Published:2017-12-30 Issue:4 Volume:67 Page:563-573
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

McGuire Helen M.,Shklovskaya Elena,Edwards Jarem,Trevillian Paul R.,McCaughan Geoffrey W.,Bertolino Patrick,McKenzie Catriona,Gourlay Ralph,Gallagher Stuart J.,Fazekas de St. Groth Barbara,Hersey Peter

Funder

National Health and Medical Research Council

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/article/10.1007/s00262-017-2107-7/fulltext.html

Reference39 articles.

1. Hersey P, Gowrishankar K (2015) Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma. Future Oncol 11(1):133–140. https://doi.org/10.2217/fon.14.205

2. Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375–384. https://doi.org/10.1016/S1470-2045(15)70076-8

3. Ugurel S, Rohmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C (2016) Survival of patients with advanced metastatic melanoma: the impact of novel therapies. Eur J Cancer 53:125–134. https://doi.org/10.1016/j.ejca.2015.09.013

4. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C (2016) Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315(15):1600–1609. https://doi.org/10.1001/jama.2016.4059

5. Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA (2016) Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17(11):1558–1568. https://doi.org/10.1016/S1470-2045(16)30366-7

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatobiliary complications of immune checkpoint inhibitors in cancer;Exploration of Targeted Anti-tumor Therapy;2024-07-26

2. New advances in the study of PD-1/PD-L1 inhibitors-induced liver injury;International Immunopharmacology;2024-04

3. Corticosteroid-resistant immune-related adverse events: a systematic review;Journal for ImmunoTherapy of Cancer;2024-01

4. Effectiveness of tacrolimus in a case of immune checkpoint inhibitor-induced hepatotoxicity that was refractory to steroids and mycophenolate mofetil;Clinical Journal of Gastroenterology;2023-07-22

5. Treatment of Refractory Checkpoint-Inhibitor-Induced Hepatitis with Tacrolimus: A Case and Review of the Literature;International Journal of Translational Medicine;2023-06-30